Vaishali Pharma Limited has informed the Exchange regarding Board meeting held on August 11, 2025.
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaishali Pharma's board, which met on August 11, 2025, approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025), along with the FY24-25 Annual Report and the notice for the 18th AGM scheduled for September 22, 2025. Revenue from operations rose about 31% year-on-year to ₹2,374.71 lakhs (from ₹1,807.98 lakhs in Q1 FY25). However, profit after tax fell roughly 25% YoY to ₹127.93 lakhs (from ₹169.90 lakhs), dragged down by higher purchases and other expenses. On a sequential basis, the company swung back to profit after reporting a loss of ₹429.25 lakhs in Q4 FY25. The statutory auditor, Raman S. Shah & Associates, issued an unmodified limited review report with no qualifications or emphasis of matter.
Mixed picture for shareholders – strong top-line growth signals improving demand, but the YoY profit decline shows margin pressure from rising costs. The clean auditor's review and return to profitability after the Q4 loss are mildly positive, though investors may watch whether revenue growth can be sustained without further profit erosion.